Gyre Therapeutics reports Q3 2025 net income of $5.9M, cuts FY revenue guidance to $115-118M

GYRE THERAPEUTICS, INC.

2025-Q3 EPS reported $0.04 vs consensus $0.03 ▲ beat (+47.1%)

Q3 revenue $30.6M (+20% YoY), net income $5.9M (doubled), adjusted net income $8.8M.
Full-year revenue guidance lowered to $115-118M from $118-128M due to Etorel rollout delays.
Nine-month 2025 revenue $79.4M, net income $11.2M vs $17.3M YoY; basic EPS $0.08.
Cash $80.3M as of Sept 30; completed Phase 3 pneumoconiosis trial enrollment (272 patients).
Hydronidone NDA in China progressing; US IND for MASH delayed to 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.